TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 4.50B USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | (m) | |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities |
| Total assets | 39.86B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $4.50B | (m) | (m) | (m) | $39.86B | (m) |
| 2026-03-31 | (m) | (m) | $2.60B | (m) | (m) | (m) | $40.04B | (m) |
| 2025-12-31 | (m) | (m) | $1.80B | (m) | (m) | (m) | $40.75B | (m) |
| 2025-09-30 | (m) | (m) | $1.00M | (m) | (m) | (m) | $39.86B | (m) |
| 2025-06-30 | (m) | (m) | $441.00M | (m) | (m) | (m) | $40.13B | (m) |
| 2025-03-31 | (m) | (m) | $398.00M | (m) | (m) | (m) | $38.41B | (m) |
| 2024-12-31 | (m) | (m) | $1.76B | (m) | (m) | (m) | $39.33B | (m) |
| 2024-09-30 | (m) | (m) | $2.56B | (m) | (m) | (m) | $41.76B | (m) |
| 2024-06-30 | (m) | (m) | $2.07B | (m) | (m) | (m) | $41.34B | (m) |
| 2024-03-31 | (m) | (m) | $3.04B | (m) | (m) | (m) | $42.77B | (m) |
| 2023-12-31 | (m) | (m) | $1.65B | (m) | (m) | (m) | $43.48B | (m) |
| 2023-09-30 | (m) | (m) | $956.00M | (m) | (m) | (m) | $42.09B | (m) |
| 2023-06-30 | (m) | (m) | $1.96B | (m) | (m) | (m) | $43.09B | (m) |
| 2023-03-31 | (m) | (m) | $1.00B | (m) | (m) | (m) | $43.46B | (m) |
| 2022-12-31 | (m) | (m) | $2.09B | (m) | (m) | (m) | $44.01B | (m) |
| 2022-09-30 | (m) | (m) | $2.75B | (m) | (m) | (m) | $44.25B | (m) |
| 2022-06-30 | (m) | (m) | $1.70B | (m) | (m) | (m) | $45.93B | (m) |
| 2022-03-31 | (m) | (m) | $2.05B | (m) | (m) | (m) | $47.06B | (m) |
| 2021-12-31 | (m) | (m) | $1.40B | (m) | (m) | (m) | $47.67B | (m) |
| 2021-09-30 | (m) | (m) | $2.39B | (m) | (m) | (m) | $47.85B | (m) |
| 2021-06-30 | (m) | (m) | $3.51B | (m) | (m) | (m) | $49.20B | (m) |
| 2021-03-31 | (m) | (m) | $2.67B | (m) | (m) | (m) | $49.00B | (m) |
| 2020-12-31 | (m) | (m) | $2.67B | (m) | (m) | (m) | $50.64B | (m) |
| 2020-09-30 | (m) | (m) | $1.47B | (m) | (m) | (m) | $49.74B | (m) |
| 2020-06-30 | (m) | (m) | $1.14B | (m) | (m) | (m) | $54.99B | (m) |
| 2020-03-31 | (m) | (m) | $1.12B | (m) | (m) | (m) | $55.33B | (m) |
| 2019-12-31 | (m) | (m) | $1.83B | (m) | (m) | (m) | $57.47B | (m) |
| 2019-09-30 | (m) | (m) | $2.52B | (m) | (m) | (m) | $57.25B | (m) |
| 2019-06-30 | (m) | (m) | $2.26B | (m) | (m) | (m) | $59.42B | (m) |
| 2019-03-31 | (m) | (m) | $2.27B | (m) | (m) | (m) | $59.85B | (m) |
| 2018-12-31 | (m) | (m) | $1.70B | (m) | (m) | (m) | $60.68B | (m) |
| 2018-09-30 | (m) | (m) | $2.16B | (m) | (m) | (m) | $65.06B | (m) |
| 2018-06-30 | (m) | (m) | $757.00M | (m) | (m) | (m) | $67.03B | (m) |
| 2018-03-31 | (m) | (m) | $786.00M | (m) | (m) | (m) | $69.18B | (m) |
| 2017-12-31 | (m) | (m) | $2.88B | (m) | (m) | (m) | $70.61B | (m) |
| 2017-09-30 | (m) | (m) | $1.90B | (m) | (m) | (m) | $86.08B | (m) |
| 2017-06-30 | (m) | (m) | $265.00M | (m) | (m) | (m) | $86.36B | (m) |
| 2017-03-31 | (m) | (m) | $835.00M | (m) | (m) | (m) | $91.28B | (m) |
| 2016-12-31 | (m) | (m) | $810.00M | (m) | (m) | (m) | $92.89B | (m) |
| 2016-03-31 | (m) | (m) | $950.00M | (m) | (m) | (m) | $55.13B | (m) |
| 2015-12-31 | (m) | (m) | $989.00M | (m) | (m) | (m) | $54.26B | (m) |
| 2014-12-31 | (m) | (m) | $1.19B | (m) | (m) | (m) | $46.42B | (m) |
| 2013-12-31 | (m) | (m) | $816.00M | (m) | (m) | (m) | $47.51B | (m) |
| 2012-12-31 | (m) | (m) | $2.43B | (m) | (m) | (m) | $50.61B | (m) |
| 2011-12-31 | (m) | (m) | $1.16B | (m) | (m) | (m) | $50.14B | (m) |
| 2010-12-31 | (m) | (m) | $690.00M | (m) | (m) | (m) | $38.15B | (m) |
| 2009-12-31 | (m) | (m) | $564.00M | (m) | (m) | (m) | $33.21B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.